Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose ...

Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and ...

With this extension, IXCHIQ ® , the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 ...

Significant regulatory progress was made with IXCHIQ, including three additional approvals and ongoing label extension activities. The company expanded market access for IXCHIQ, launching in ...

The Schall Law investigates Valneva after CDC links its vaccine to hospitalizations. Investors may have legal options.

SE ADR (NASDAQ:VALN) stock closed up 12.1% following the announcement that the Brazilian Health Regulatory Agency (ANVISA) has granted the first marketing authorization for its chikungunya vaccine, ...

However, challenges such as the slower-than-expected ramp-up of IXCHIQ and regulatory delays in Brazil were acknowledged. Nevertheless, Valneva’s strategic initiatives and successful financial ...

This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of IXCHIQ ® label to adolescents in the European Union (EU) 2. IXCHIQ ® is the world’s ...

With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).